Eversept Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Eversept Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-176,594	Closed	-$4.72M	–	121
2025 Q4	$4.72M	Buy	176,594 +12,357	+8%	+$295K	0.24%	71
2025 Q3	$3.5M	Buy	+164,237	New	+$3.88M	0.24%	58
2021 Q2	–	Sell	-420,000	Closed	-$9.48M	–	88
2021 Q1	$10.8M	Buy	+420,000	New	+$18.5M	0.81%	33

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners's ACAD Position: Q1 2026 in Review

Eversept Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 176,594 shares — an estimated $4.72M sold.

Eversept Partners first reported a position in ACAD in Q1 2021 and held it in 3 quarters. The position peaked at $10.8M in Q1 2021. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Eversept Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Eversept Partners sold 176,594 Acadia Pharmaceuticals shares in Q1 2026, an estimated $4.72M.
Eversept Partners first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Eversept Partners's Acadia Pharmaceuticals position peaked at $10.8M in Q1 2021.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.